Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects.

Keller J, Trautmann ME, Haber H, Tham LS, Hunt T, Mace K, Linnebjerg H

Regulatory peptides6 Sept 2012Cited by 62 (Europe PMC)

PMID22960288DOI10.1016/j.regpep.2012.08.005PepBankPUB-22960288

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialActivity measurement
In fasting healthy subjects, exenatide did not affect pre-CCK gallbladder volume compared with placebo.
In plain wordsIn fasting healthy people, exenatide did not change gallbladder volume before CCK compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changePre-CCK gallbladder volume
Study
n: not reported in source
Comparator
placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
10 μg · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
Administration of exenatide did not affect pre-CCK infusion gallbladder volume or EF compared to placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Healthy subjects participated in this randomized, 2-period, double-blind crossover study.
Summary · context
Fasting subjects received a single subcutaneous injection of exenatide (10 μg) or placebo 60 min before CCK infusion.
Report a problemFND-2296028801
02HumanRandomized controlled trialActivity measurement
In fasting healthy subjects, exenatide did not affect pre-CCK gallbladder ejection fraction compared with placebo.
In plain wordsIn fasting healthy people, exenatide did not change gallbladder emptying before CCK compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changePre-CCK ejection fraction
Study
n: not reported in source
Comparator
placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
10 μg · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
Administration of exenatide did not affect pre-CCK infusion gallbladder volume or EF compared to placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Healthy subjects participated in this randomized, 2-period, double-blind crossover study.
Summary · context
Fasting subjects received a single subcutaneous injection of exenatide (10 μg) or placebo 60 min before CCK infusion.
Report a problemFND-2296028802
03HumanRandomized controlled trialActivity measurement
In fasting healthy subjects, minimum gallbladder volume during CCK was similar with exenatide and placebo.
In plain wordsIn fasting healthy people, minimum gallbladder volume during CCK was similar with exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeMinimum gallbladder volume during CCK
Study
n: not reported in source
Comparator
placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
10 μg · subcutaneous · single doseAs given in this study (human).
Measurements
Minimum gallbladder volume
13.68 mL
exenatide
Minimum gallbladder volume
11.05 mL
placebo
LSM difference in minimum gallbladder volume
2.62 mL
exenatide minus placebo
95% CI of LSM difference in minimum gallbladder volume
−0.53 to 5.78 mL
exenatide minus placebo
Source sentences
Summary
During the CCK-infusion, the mean minimum gallbladder volume was similar for exenatide (13.68 mL) and placebo (11.05 mL) (least squares mean [LSM] difference of 2.62 mL; 95% confidence interval [CI], -0.53, 5.78)
2 context sentences(design, population, supporting numbers)
Summary · context
Healthy subjects participated in this randomized, 2-period, double-blind crossover study.
Summary · context
Fasting subjects received a single subcutaneous injection of exenatide (10 μg) or placebo 60 min before CCK infusion.
Report a problemFND-2296028803
04HumanRandomized controlled trialActivity measurement
In fasting healthy subjects, exenatide lowered maximum gallbladder ejection fraction during CCK compared with placebo.
In plain wordsIn fasting healthy people, exenatide reduced maximum gallbladder emptying during CCK compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseMaximum gallbladder ejection fraction during CCK
Study
n: not reported in source
Comparator
placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
10 μg · subcutaneous · single doseAs given in this study (human).
Measurements
Maximum ejection fraction
28.79%
exenatide
Maximum ejection fraction
46.13%
placebo
LSM difference in maximum ejection fraction
−17.34%
exenatide minus placebo
95% CI of LSM difference in maximum ejection fraction
−30.54 to −4.13%
exenatide minus placebo
Source sentences
Summary
but the mean maximum EF was lower for exenatide (28.79%) versus placebo (46.13%) (LSM difference of -17.34%; 95% CI, -30.54, -4.13).
2 context sentences(design, population, supporting numbers)
Summary · context
Healthy subjects participated in this randomized, 2-period, double-blind crossover study.
Summary · context
Fasting subjects received a single subcutaneous injection of exenatide (10 μg) or placebo 60 min before CCK infusion.
Report a problemFND-2296028804
05HumanRandomized controlled trialActivity measurement
In fasting healthy subjects, exenatide had no clinically significant effect on pancreatic duct diameter compared with placebo.
In plain wordsIn fasting healthy people, exenatide had no clinically significant effect on pancreatic duct width compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changePancreatic duct diameter
Study
n: not reported in source
Comparator
placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
10 μg · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
Exenatide had no clinically significant effects on pancreatic or bile duct diameters.
2 context sentences(design, population, supporting numbers)
Summary · context
Healthy subjects participated in this randomized, 2-period, double-blind crossover study.
Summary · context
Fasting subjects received a single subcutaneous injection of exenatide (10 μg) or placebo 60 min before CCK infusion.
Report a problemFND-2296028805
06HumanRandomized controlled trialActivity measurement
In fasting healthy subjects, exenatide had no clinically significant effect on bile duct diameter compared with placebo.
In plain wordsIn fasting healthy people, exenatide had no clinically significant effect on bile duct width compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBile duct diameter
Study
n: not reported in source
Comparator
placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
10 μg · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
Exenatide had no clinically significant effects on pancreatic or bile duct diameters.
2 context sentences(design, population, supporting numbers)
Summary · context
Healthy subjects participated in this randomized, 2-period, double-blind crossover study.
Summary · context
Fasting subjects received a single subcutaneous injection of exenatide (10 μg) or placebo 60 min before CCK infusion.
Report a problemFND-2296028806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.